Billionaire David E. Shaw‘s D E Shaw has recently filed a Form 13G with the US SEC in which it reported holding 3.74 million common shares of Biocryst Pharmaceuticals Inc (NASDAQ:BCRX), which account for 5.1% of the company’s outstanding stock. This represents an increase in the stake as the fund previously held 3.43 million shares, as disclosed in its last 13F filing, for the end of June.
Biocryst Pharmaceuticals is a pharmaceutical company engaged in the development and production of novel small-molecule therapies that block key enzymes and help treat many rare disorders. Recently, the company announced the start of the APeX-1 Clinical Trial of BCX7353 for treating hereditary angioedema, and the first results of the trial are expected at the end of the year. For the second quarter of 2016, Biocryst Pharmaceuticals reported revenue of $4.79 million and a loss per share of $0.22, compared to revenue of $25.84 million and earnings per basic share of $0.07 for the same period in the previous year. Earlier this month, Piper Jaffray upgraded its rating on Biocryst Pharmaceuticals’ stock to ‘Overweight’ from ‘Neutral’ and raised its price target to $8.00 from $5.00, while HC Wainwright reiterated its ‘Buy’ rating and JP Morgan Chase & Co. reiterated its ‘Hold’ rating.
At the end of June, investors from our database that were bullish on Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) also included Anders Hove and Bong Koh’s VHCP Management, with a position valued at close to $2.9 million, Chuck Royce’s Royce & Associates, with a $454,000 position, Gavin Saitowitz and Cisco J. Del Valle’s Springbok Capital, and Ken Greenberg and David Kim’s Ghost Tree Capita, which initiated a new position and had $4.83 million invested in the company. A fund that decided to sell its position in Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) was Jim Simons’ Renaissance Technologies.
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| D. E. Shaw Co. | 0 | 3,698,639 | 0 | 3,740,239 | 3,740,239 | 5.1% |
| David E. Shaw | 0 | 3,698,639 | 0 | 3,740,239 | 3,740,239 | 5.1% |
Follow David E. Shaw's D E Shaw
Page 1 of 6 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
BioCryst Pharmaceuticals, Inc.
(Name of Issuer)
Common stock, par value $0.01
(Title of Class of Securities)
09058V103
(CUSIP Number)
August 11, 2016
(Date of Event Which Requires Filing of
this Statement)
Check the following box to designate the rule pursuant to which
the Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
